{"formatVersion":"1.1","id":"https://www.mentalhealth.com/library/maois","path":"/library/maois","url":"https://www.mentalhealth.com/library/maois","title":"Monoamine Oxidase Inhibitors (MAOIs)","family":"Library detail","description":"Monoamine oxidase inhibitors, commonly referred to as MAOIs, are a type of antidepressant medication used to treat a range of mental health conditions.","language":"en-US","access":{"audience":"public","indexable":true},"provenance":{"sourceUrl":"https://www.mentalhealth.com/library/maois","wordpressId":"593","contentCompleteness":"complete","dateScope":"original-source"},"authors":[{"@type":"Person","@id":"https://www.mentalhealth.com/people/naomi-carr#person","name":"Naomi Carr","url":"https://www.mentalhealth.com/people/naomi-carr"}],"reviewer":{"@type":"Person","@id":"https://www.mentalhealth.com/people/morgan-blair#person","name":"Morgan Blair","url":"https://www.mentalhealth.com/people/morgan-blair"},"dates":{"datePublished":"2023-09-11T12:01:21Z","dateModified":"2025-08-24T20:06:42Z","lastReviewed":"2023-09-11"},"content":{"html":"<nav aria-label=\"Breadcrumb\" class=\"breadcrumbs\"><ol><li><a href=\"https://www.mentalhealth.com/\">Home</a></li><li><a href=\"https://www.mentalhealth.com/library\">Library</a></li><li><a href=\"https://www.mentalhealth.com/library/medications\">Medications</a></li><li><span aria-current=\"page\">Monoamine Oxidase Inhibitors (MAOIs)</span></li></ol></nav><div class=\"article-page article-standard\" data-library-standard=\"\"><div class=\"article-main-grid\"><header class=\"article-heading\"><h1>Monoamine Oxidase Inhibitors (MAOIs)</h1><p class=\"article-inline-credits\"><span class=\"credit-row\"><span>Written by <a class=\"article-credit-person\" href=\"https://www.mentalhealth.com/people/naomi-carr\">Naomi Carr</a></span><span>Medically reviewed by <a class=\"article-credit-person\" href=\"https://www.mentalhealth.com/people/morgan-blair\">Morgan Blair, M.A.</a></span></span></p><div class=\"article-dates\"><span>Published on <time datetime=\"2023-09-11T12:01:21Z\">September 11, 2023</time></span><span aria-hidden=\"true\"> · </span><span>Updated on <time datetime=\"2025-08-24T20:06:42Z\">August 24, 2025</time></span></div></header><div class=\"article-jumpbar\"></div><div class=\"article-layout\"><div class=\"article-reading\"><article class=\"prose\" id=\"article-content\"><div class=\"article-intro\" data-source-field=\"hero\"><p>Monoamine oxidase inhibitors, or MAOIs, are a type of antidepressant medication used to treat mental health and neurological conditions. MAOIs are no longer a first choice in treating depression unless in specific and necessary circumstances due to their potential risks. Alternative medications and treatments are available if required.</p></div><figure class=\"article-feature\"><img alt=\"A healthcare professional rests a reassuring hand on a patient's knee.\" decoding=\"async\" height=\"630\" loading=\"eager\" src=\"https://www.mentalhealth.com/assets/optimized/8debdbe7c5f9c329801a75ed.webp\" width=\"1200\" srcset=\"/assets/responsive/05f52c7b2d553cf8657dd303.webp 800w, /assets/optimized/8debdbe7c5f9c329801a75ed.webp 1200w\" sizes=\"(max-width: 800px) 100vw, 1200px\"></figure><section aria-labelledby=\"key-takeaways\" class=\"article-takeaways\"><h2 id=\"key-takeaways\">Key takeaways</h2><ul><li>MAOIs reduce the breakdown of certain neurotransmitters and are used for selected depressive and neurological conditions.</li><li>They are generally not first-choice antidepressants because of side effects and interaction risks.</li><li>Medication combinations and tyramine-containing foods can cause serious reactions, requiring careful prescribing and dietary guidance.</li></ul></section><span id=\"what-are-maois-monoamine-oxidase-inhibitors-maois-are-a-type-of\" class=\"section-anchor-alias\" data-section-alias=\"what-are-maois\" aria-hidden=\"true\"></span><h2 id=\"what-are-maois\">What are MAOIs?</h2><p>\nMonoamine oxidase inhibitors (MAOIs) are a type of <a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/antidepressants\">antidepressant medication</a>. They were the first antidepressants developed in the 1950s and are still used today to treat depressive disorders and neurological conditions⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#mao-inhibitors\" data-reference-link=\"\" aria-label=\"Reference 1: Sabri, M.A., &amp; Saber-Ayad, M.M. (2023). MAO Inhibitors. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine.\" data-reference-number=\"1\">[1]</a></sup>.\n</p><p>MAOIs can cause various side effects, dietary restrictions, and health risks, so they are not typically used as a first-line treatment but are still used in necessary circumstances, as they can be effective treatments⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care\" data-reference-link=\"\" aria-label=\"Reference 2: Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a></sup>.\n</p><span id=\"what-are-maois-used-to-treat-the-fda-has-approved-some-maois-to-treat-major-depressive-disorder\" class=\"section-anchor-alias\" data-section-alias=\"what-are-maois-used-to-treat\" aria-hidden=\"true\"></span><h2 id=\"what-are-maois-used-to-treat\">What are MAOIs used to treat?</h2><p>\nThe FDA has approved some MAOIs to treat major depressive disorder⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a></sup>. It is advised not to use MAOIs as a first-line treatment for depression due to their potential risks. However, MAOIs may be the preferred treatment for treatment-resistant depression or <a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/atypical-depression\">atypical depression</a>, with symptoms such as anxiety, increased sleep, or changes in appetite⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#nardil-phenelzine-sulfate-tablets-usp-fda\" data-reference-link=\"\" aria-label=\"Reference 4: Parke-Davis, Pfizer, Inc. (2007). Nardil (Phenelzine Sulfate Tablets, USP).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"4\">[4]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#atypical-depression\" data-reference-link=\"\" aria-label=\"Reference 5: Singh, T., &amp; Williams, K. (2006). Atypical Depression. Psychiatry (Edgmont (Pa.: Township)), 3(4), 33–39. National Library of Medicine. PubMed Central. Accessed November 19 2022.\" data-reference-number=\"5\">[5]</a></sup>.\n</p><p>Other MAOIs have been FDA-approved for use in treating Parkinson’s disease. They may be used alone or alongside levodopa, a commonly used medication for Parkinson’s, and help to reduce motor symptoms⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#medications-parkinson-s\" data-reference-link=\"\" aria-label=\"Reference 6: American Parkinson Disease Association. (2023). Medications for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.\" data-reference-number=\"6\">[6]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#zelapar-selegiline-hydrochloride-orally-disintegrating-tablets\" data-reference-link=\"\" aria-label=\"Reference 7: Valeant Pharmaceuticals North America. (2008). Zelapar (Selegiline Hydrochloride) Orally Disintegrating Tablets. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"7\">[7]</a></sup>.</p><p>\nMAOIs are occasionally used off-label for uses that are not FDA-approved. This includes⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#mao-inhibitors\" data-reference-link=\"\" aria-label=\"Reference 1: Sabri, M.A., &amp; Saber-Ayad, M.M. (2023). MAO Inhibitors. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine.\" data-reference-number=\"1\">[1]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#purves-d-augustine-g-j-fitzpatrick-d-katz-l\" data-reference-link=\"\" aria-label=\"Reference 8: The Biogenic Amines. (2001). In Purves, D., Augustine, G.J., Fitzpatrick, D., Katz, L.C., LaMantia, A-S., McNamara, J.O., &amp; Williams, S.M. (Eds.) Neuroscience, 2nd Edition. Sunderland, MA: Sinauer Associates. National Library of Medicine.\" data-reference-number=\"8\">[8]</a></sup>:\n</p><ul>\n<li>Depressive episodes in <a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/bipolar-disorder\">bipolar disorder</a></li>\n<li>Anxiety disorders, particularly social phobia and <a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/panic-attacks-in-anxiety-disorders\">panic disorder</a></li>\n<li>Attention-deficit/hyperactivity disorder (ADHD)</li>\n<li><a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/sleep-disorders\">Narcolepsy</a></li>\n</ul><span id=\"how-do-maois-work-monoamine-oxidase-is-an-enzyme-in-the-brain-responsible-for-degrading-and-regulating-several-neurotransmitters-including-serotonin-dopamine-and-norepinephrine-these-neurotransmitters-are-known-as-amine-neurotransmitters-and-help-regulate-several-functions-including-mood-behavior-energy-cognition-and-sleep\" class=\"section-anchor-alias\" data-section-alias=\"how-do-maois-work\" aria-hidden=\"true\"></span><h2 id=\"how-do-maois-work\">How do MAOIs work?</h2><p>\nMonoamine oxidase is an enzyme in the brain responsible for degrading and regulating several neurotransmitters, including serotonin, dopamine, and norepinephrine. These neurotransmitters are known as amine neurotransmitters and help regulate several functions, including mood, behavior, energy, cognition, and sleep⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#mao-inhibitors\" data-reference-link=\"\" aria-label=\"Reference 1: Sabri, M.A., &amp; Saber-Ayad, M.M. (2023). MAO Inhibitors. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine.\" data-reference-number=\"1\">[1]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#inhibitors-mao-mao-b-psychiatry-neurology\" data-reference-link=\"\" aria-label=\"Reference 9: Finberg, J.P., &amp; Rabey, J.M. (2016). Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Frontiers in Pharmacology, 7, 340. Frontiers. Accessed October 10 2026.\" data-reference-number=\"9\">[9]</a></sup>.\n</p><p>MAO inhibitors prevent the monoamine oxidase enzyme from breaking down these neurotransmitters, thereby increasing their levels. Reduced levels of amine neurotransmitters, particularly serotonin, are known to be involved in the development of depression, so by increasing these levels, MAOIs cause an antidepressant effect⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#emsam-selegiline-transdermal-system-fda\" data-reference-link=\"\" aria-label=\"Reference 10: Somerset Pharmaceuticals Inc. (2014). Emsam (Selegiline Transdermal System).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"10\">[10]</a></sup>.</p><p>There are two types of monoamine oxidase enzymes, called MAO-A and MAO-B. MAO-A impacts serotonin, dopamine, and norepinephrine. In contrast, MAO-B does not impact serotonin but also affects dopamine and norepinephrine⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#mao-inhibitors\" data-reference-link=\"\" aria-label=\"Reference 1: Sabri, M.A., &amp; Saber-Ayad, M.M. (2023). MAO Inhibitors. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine.\" data-reference-number=\"1\">[1]</a></sup>.</p><p>There are three types of MAOIs: ones that selectively inhibit MAO-A, ones that selectively inhibit MAO-B, and ones that are not selective, thus inhibiting both MAO-A and MAO-B. As such, each of these MAOIs can cause different effects, with those that inhibit MAO-A having a more substantial antidepressant effect than those that only inhibit MAO-B⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#emsam-selegiline-transdermal-system-fda\" data-reference-link=\"\" aria-label=\"Reference 10: Somerset Pharmaceuticals Inc. (2014). Emsam (Selegiline Transdermal System).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"10\">[10]</a></sup>.</p><p>However, as MAO-A also metabolizes dietary tyramine, MAO-A inhibitors prevent this from occurring, allowing tyramine to enter the bloodstream. This triggers the release of norepinephrine, which results in an increase in blood pressure and a hypertensive crisis, commonly referred to as the ‘cheese effect’⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care\" data-reference-link=\"\" aria-label=\"Reference 2: Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#emsam-selegiline-transdermal-system-fda\" data-reference-link=\"\" aria-label=\"Reference 10: Somerset Pharmaceuticals Inc. (2014). Emsam (Selegiline Transdermal System).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"10\">[10]</a></sup>.</p><p>\nMost MAOIs are administered as an oral tablet, which enters the gastrointestinal tract. But a transdermal patch has been developed to provide the antidepressant effects of MAOIs while preventing the ‘cheese effect’, as the medication is absorbed directly into the bloodstream⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care\" data-reference-link=\"\" aria-label=\"Reference 2: Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#withdrawal-effects-antidepressants\" data-reference-link=\"\" aria-label=\"Reference 11: Mind. (2020). Withdrawal Effects of Antidepressants. Mind. Mind. Accessed October 10 2026.\" data-reference-number=\"11\">[11]</a></sup>.\n</p><span id=\"types-of-maois-there-are-various-types-of-maois-categorized-as-mao-a-inhibitors-mao-b-inhibitors-and-nonselective-maois\" class=\"section-anchor-alias\" data-section-alias=\"types-of-maois\" aria-hidden=\"true\"></span><h2 id=\"types-of-maois\">Types of MAOIs</h2><p>\nThere are various types of MAOIs, categorized as MAO-A inhibitors, MAO-B inhibitors, and nonselective MAOIs⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#medications-parkinson-s\" data-reference-link=\"\" aria-label=\"Reference 6: American Parkinson Disease Association. (2023). Medications for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.\" data-reference-number=\"6\">[6]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#emsam-selegiline-transdermal-system-fda\" data-reference-link=\"\" aria-label=\"Reference 10: Somerset Pharmaceuticals Inc. (2014). Emsam (Selegiline Transdermal System).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"10\">[10]</a></sup>:\n</p><h3 id=\"mao-a-inhibitors\">MAO-A inhibitors</h3><ul>\n<li><strong>Clorgyline: </strong>Clorgyline is not used clinically.</li>\n<li><strong><a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/moclobemide-uses-dosage-side-effects\">Moclobemide</a>: </strong>Moclobemide is not approved for use in the US but is used in other parts of the world for depression and social phobia.</li>\n</ul><h3 id=\"mao-b-inhibitors\">MAO-B inhibitors</h3><ul>\n<li><strong>Selegiline: </strong>Selegiline is FDA-approved in the treatment of Parkinson’s disease. It is available as an oral tablet to be swallowed whole under the brand names L-deprenyl and Eldepryl. It is also available as an orally disintegrating tablet under the brand name Zelapar.</li>\n<li><strong>Rasagiline: </strong>Rasagiline is FDA-approved for treating Parkinson’s disease. It is available as a tablet under the brand name Azilect.</li>\n<li><strong>Safinamide: </strong>Safinamide is FDA-approved for treating Parkinson’s disease. It is available as a tablet under the brand name Xadago.</li>\n</ul><h3 id=\"nonselective-maois\">Nonselective MAOIs</h3><ul>\n<li><strong><a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/phenelzine-uses-dosage-side-effects\">Phenelzine</a>: </strong>Phenelzine is FDA-approved for the treatment of depression. It is available as a tablet under the brand name Nardil.</li>\n<li><strong>Tranylcypromine: </strong>Tranylcypromine is FDA-approved for the treatment of depression. It is available as a tablet under the brand name Parnate.</li>\n<li><strong>Isocarboxazid: </strong>Isocarboxazid is FDA-approved to treat depression. It is available as a tablet under the brand name Marplan.</li>\n<li><strong>Transdermal Selegiline: </strong>Transdermal selegiline is FDA-approved to treat depression. It is available as a skin patch under the brand name Emsam.</li>\n</ul><span id=\"side-effects-of-maois-common-short-term-side-effects-of-maois-include\" class=\"section-anchor-alias\" data-section-alias=\"side-effects-of-maois\" aria-hidden=\"true\"></span><h2 id=\"side-effects-of-maois\">Side effects of MAOIs</h2><p>\nCommon short-term side effects of MAOIs include⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care\" data-reference-link=\"\" aria-label=\"Reference 2: Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#medications-parkinson-s\" data-reference-link=\"\" aria-label=\"Reference 6: American Parkinson Disease Association. (2023). Medications for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.\" data-reference-number=\"6\">[6]</a></sup>:\n</p><ul>\n<li>Nausea</li>\n<li>Drowsiness</li>\n<li>Dizziness</li>\n<li>Insomnia</li>\n<li>Stomach upset, including diarrhea and constipation</li>\n<li><strong>Increased suicidal ideation: </strong>This risk is higher in people under the age of 24 and within the first few weeks or months of a new treatment. If you notice emerging or increasing thoughts of self-harm or suicide when commencing MAOI treatment, inform your doctor or mental health professional immediately.</li>\n</ul><p>\nPossible side effects of long-term MAOI use include⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care\" data-reference-link=\"\" aria-label=\"Reference 2: Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#nardil-phenelzine-sulfate-tablets-usp-fda\" data-reference-link=\"\" aria-label=\"Reference 4: Parke-Davis, Pfizer, Inc. (2007). Nardil (Phenelzine Sulfate Tablets, USP).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"4\">[4]</a></sup>:\n</p><ul>\n<li>Weight gain</li>\n<li>Sexual dysfunction</li>\n<li>Muscle pain</li>\n<li>Muscle spasms</li>\n<li>Numbness and tingling</li>\n<li>Difficulty passing urine</li>\n</ul><p>\nMAOI withdrawal symptoms can occur when abruptly stopping the medication. This can include⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#mao-inhibitors\" data-reference-link=\"\" aria-label=\"Reference 1: Sabri, M.A., &amp; Saber-Ayad, M.M. (2023). MAO Inhibitors. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine.\" data-reference-number=\"1\">[1]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#depression-adults\" data-reference-link=\"\" aria-label=\"Reference 12: National Health Service. (2023). Depression in Adults. NHS. NHS. Accessed October 10 2026.\" data-reference-number=\"12\">[12]</a></sup>:\n</p><ul>\n<li>Nausea</li>\n<li>Vomiting</li>\n<li>Fatigue</li>\n<li>Agitation</li>\n<li>Irritability</li>\n<li>Insomnia</li>\n<li>Psychotic symptoms such as delusions and hallucinations</li>\n</ul><p>\nTo prevent withdrawal, your doctor will likely reduce your dose gradually. It is important not to suddenly stop MAOI treatment, as this can increase the risk of withdrawal symptoms.\n</p><h2 id=\"possible-interactions-with-maois\">Possible interactions with MAOIs</h2><h3 id=\"serotonin-syndrome-maois-can-contribute-to-the-onset-of-serotonin-syndrome-if-used-alongside-other-antidepressants-or-medications-that-increase-serotonin-dangerously-high-serotonin-levels-can-cause-serotonin-syndrome-and-can-in-some-cases-be-fatal-symptoms-of-serotonin-syndrome-include\">Serotonin syndrome</h3><p>\nMAOIs can contribute to the onset of serotonin syndrome if used alongside other antidepressants or medications that increase serotonin. Dangerously high serotonin levels can cause serotonin syndrome and can, in some cases, be fatal. Symptoms of serotonin syndrome include⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care\" data-reference-link=\"\" aria-label=\"Reference 2: Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#withdrawal-effects-antidepressants\" data-reference-link=\"\" aria-label=\"Reference 11: Mind. (2020). Withdrawal Effects of Antidepressants. Mind. Mind. Accessed October 10 2026.\" data-reference-number=\"11\">[11]</a></sup>:\n</p><ul>\n<li>Fatigue</li>\n<li>Change in mental state</li>\n<li>Hallucinations</li>\n<li>Stomach pain</li>\n<li>Diarrhea</li>\n<li>Kidney failure</li>\n<li>Shaking</li>\n<li>Irregular heartbeat</li>\n<li>Fever</li>\n<li>Sweating</li>\n</ul><p>\nIt is advised not to use MAOIs while using SSRIs, SNRIs, TCAs, other MAOIs, bupropion, and amphetamines. When changing between one of these medications and an MAOI, it is advised to wait at least 14 days between the last dose of the previous medication and the first dose of the next. For medicines with longer half-lives, such as fluoxetine, it is necessary to wait longer⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care\" data-reference-link=\"\" aria-label=\"Reference 2: Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a></sup>.\n</p><h3 id=\"cheese-effect-the-hypertensive-crisis-that-maois-can-cause-is-often-called-the-cheese-effect-it-is-caused-by-the-impact-maois-have-on-tyramine-metabolization-in-the-intestines-the-cheese-effect-can-cause-severe-and-potentially-fatal-issues-including\">‘Cheese effect’</h3><p>\nThe hypertensive crisis that MAOIs can cause is often called the ‘cheese effect’. It is caused by the impact MAOIs have on tyramine metabolization in the intestines. The ‘cheese effect’ can cause severe and potentially fatal issues, including⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#nardil-phenelzine-sulfate-tablets-usp-fda\" data-reference-link=\"\" aria-label=\"Reference 4: Parke-Davis, Pfizer, Inc. (2007). Nardil (Phenelzine Sulfate Tablets, USP).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"4\">[4]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#emsam-selegiline-transdermal-system-fda\" data-reference-link=\"\" aria-label=\"Reference 10: Somerset Pharmaceuticals Inc. (2014). Emsam (Selegiline Transdermal System).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"10\">[10]</a></sup>:\n</p><ul>\n<li>Increased blood pressure</li>\n<li>Headaches</li>\n<li>Irregular or fast heartbeat</li>\n<li>Nausea</li>\n<li>Stroke</li>\n</ul><p>\nAs such, it is required to follow a restricted diet when taking an MAOI to help prevent this. Foods high in tyramine should be avoided or limited, such as⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care\" data-reference-link=\"\" aria-label=\"Reference 2: Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a></sup>:\n</p><ul>\n<li>Soy products</li>\n<li>Certain cheeses</li>\n<li>Bananas</li>\n<li>Certain types of meat and fish</li>\n<li>Broad bean pods</li>\n</ul><p>\nDietary restrictions are not necessary when taking MAO-B inhibitors or the MAOI transdermal patch in a low dose, as these types of MAOIs are not likely to cause this effect.\n</p><h3 id=\"drug-interactions-some-medications-can-also-cause-a-hypertensive-crisis-when-combined-with-maois-and-should-be-avoided-this-includes\">Drug interactions</h3><p>\nSome medications can also cause a hypertensive crisis when combined with MAOIs and should be avoided. This includes⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#mao-inhibitors\" data-reference-link=\"\" aria-label=\"Reference 1: Sabri, M.A., &amp; Saber-Ayad, M.M. (2023). MAO Inhibitors. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine.\" data-reference-number=\"1\">[1]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care\" data-reference-link=\"\" aria-label=\"Reference 2: Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a></sup>:\n</p><ul>\n<li>Parkinson’s medications</li>\n<li>Medications that increase dopamine, serotonin, or epinephrine</li>\n<li>Stimulants</li>\n<li>Amphetamines</li>\n<li>Opioids</li>\n<li>Tryptophan</li>\n<li>Vasoconstrictors</li>\n</ul><p>\nAlways inform your doctor of all medications you take, whether prescribed or over the counter, before starting a new treatment.\n</p><h3 id=\"precautions-people-with-heart-liver-or-kidney-conditions-may-not-be-able-to-take-maois-safely-it-is-advised-to-inform-your-doctor-of-any-existing-conditions-before-starting-maoi-treatment-as-it-may-be-unsafe-to-do-so-or-your-doctor-may-wish-to-prescribe-you-a-reduced-dose-and-ensure-careful-monitoring-of-your-physical-health\">Precautions</h3><p>\nPeople with heart, liver, or kidney conditions may not be able to take MAOIs safely. It is advised to inform your doctor of any existing conditions before starting MAOI treatment, as it may be unsafe to do so, or your doctor may wish to prescribe you a reduced dose and ensure careful monitoring of your physical health⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#nardil-phenelzine-sulfate-tablets-usp-fda\" data-reference-link=\"\" aria-label=\"Reference 4: Parke-Davis, Pfizer, Inc. (2007). Nardil (Phenelzine Sulfate Tablets, USP).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"4\">[4]</a></sup>.\n</p><span id=\"alternatives-to-maois-before-being-prescribed-maois-your-doctor-will-likely-try-an-alternative-medication-that-carries-fewer-risks\" class=\"section-anchor-alias\" data-section-alias=\"alternatives-to-maois\" aria-hidden=\"true\"></span><h2 id=\"alternatives-to-maois\">Alternatives to MAOIs</h2><p>\nBefore being prescribed MAOIs, your doctor will likely try an alternative medication that carries fewer risks.\n</p><h3 id=\"alternative-medications-for-depression-several-other-antidepressant-medications-are-available-that-will-likely-be-prescribed-before-trying-an-maoi-this-includes\">Alternative medications for depression</h3><p>\nSeveral other antidepressant medications are available that will likely be prescribed before trying an MAOI. This includes⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#self-care-depression\" data-reference-link=\"\" aria-label=\"Reference 13: Mind. (2023). Self-Care for Depression. Mind. Mind. Accessed October 10 2026.\" data-reference-number=\"13\">[13]</a></sup>:\n</p><ul>\n<li>Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline, and citalopram</li>\n<li>Serotonin and norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine, duloxetine, and levomilnacipran</li>\n<li>Tricyclic antidepressants (TCAs), such as imipramine, amitriptyline, and desipramine</li>\n<li>Atypical antidepressants, such as mirtazapine and bupropion</li>\n</ul><section aria-label=\"Subject matter expert\" class=\"article-expert article-expert-inline\" data-expert-kind=\"related\" data-expert-layout=\"standard\"><p class=\"article-bio-role\">Subject matter expert</p><div class=\"article-expert-identity\"><a href=\"https://www.mentalhealth.com/people/leila-khurshid\" class=\"card-identity-photo\" aria-label=\"Leila Khurshid, Pharm.D.\"><img alt=\"\" height=\"64\" loading=\"lazy\" src=\"https://www.mentalhealth.com/assets/optimized/90339bb61ace127cee8df5f2.webp\" width=\"64\" decoding=\"async\"></a><h2><a href=\"https://www.mentalhealth.com/people/leila-khurshid\">Leila Khurshid, Pharm.D.</a></h2></div><p class=\"article-expert-focus\">Clinical pharmacy and medication</p><a href=\"https://www.mentalhealth.com/people/leila-khurshid\" class=\"quiet-button\">View profile</a></section><h3 id=\"alternative-treatment-for-depression-alongside-antidepressant-medication-utilizing-therapy-and-self-help-techniques-is-often-very-helpful-available-therapies-that-can-be-effective-at-managing-symptoms-of-depression-include\">Alternative treatment for depression</h3><p>\nAlongside antidepressant medication, utilizing therapy and self-help techniques is often very helpful. Available therapies that can be effective at managing symptoms of depression include⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#self-care-depression\" data-reference-link=\"\" aria-label=\"Reference 13: Mind. (2023). Self-Care for Depression. Mind. Mind. Accessed October 10 2026.\" data-reference-number=\"13\">[13]</a></sup>:\n</p><ul>\n<li>Cognitive behavioral therapy (CBT)</li>\n<li>Interpersonal therapy (IPT)</li>\n<li>Psychodynamic therapy</li>\n<li>Mindfulness-based therapy</li>\n<li>Behavioral activation</li>\n<li>Family therapy</li>\n</ul><p>\nSelf-help techniques that can be beneficial for managing symptoms of depression include⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#self-care-depression\" data-reference-link=\"\" aria-label=\"Reference 13: Mind. (2023). Self-Care for Depression. Mind. Mind. Accessed October 10 2026.\" data-reference-number=\"13\">[13]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#treatment-options-parkinson-s\" data-reference-link=\"\" aria-label=\"Reference 14: American Parkinson Disease Association. (2023). Treatment Options for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.\" data-reference-number=\"14\">[14]</a></sup>:\n</p><ul>\n<li>Talking to others</li>\n<li>Keeping a mood diary</li>\n<li>Relaxation techniques</li>\n<li>Mindfulness</li>\n<li>Avoiding drugs and alcohol</li>\n<li>Spending time outside in nature</li>\n<li>Improving physical health, such as eating a healthy diet, regularly exercising, and following a sleep schedule</li>\n</ul><h3 id=\"alternative-medications-for-parkinson-s-disease-many-alternative-medications-can-be-used-to-treat-parkinson-s-disease-which-can-be-used-alongside-or-instead-of-maois-this-includes\">Alternative medications for Parkinson’s disease</h3><p>\nMany alternative medications can be used to treat Parkinson’s disease, which can be used alongside or instead of MAOIs. This includes⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/maois#medications-parkinson-s\" data-reference-link=\"\" aria-label=\"Reference 6: American Parkinson Disease Association. (2023). Medications for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.\" data-reference-number=\"6\">[6]</a></sup>:\n</p><ul>\n<li>Dopamine precursors, such as levodopa</li>\n<li>Dopamine agonists, such as pramipexole and ropinirole</li>\n<li>Anticholinergics, such as benztropine and trihexyphenidyl</li>\n</ul><p>\nAdditional treatments for Parkinson’s disease include⁠<sup class=\"citation-group\"><a href=\"https://www.mentalhealth.com/library/maois#treatment-options-parkinson-s\" class=\"article-citation\" data-reference-link=\"\" aria-label=\"Reference 14: American Parkinson Disease Association. (2023). Treatment Options for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.\" data-reference-number=\"14\">[14]</a></sup>:\n</p><ul>\n<li>Speech therapy</li>\n<li>Physical therapy</li>\n<li>Occupational therapy</li>\n<li>Deep brain stimulation (DBS)</li>\n</ul></article><div class=\"article-endmatter\"><section class=\"article-sources\" data-reference-list=\"\" data-reference-style=\"author-date-title-source\" data-source-references=\"\" id=\"references\"><h2 id=\"references-2\">References</h2><ol><li id=\"mao-inhibitors\" value=\"1\" data-reference-number=\"1\" data-reference-format=\"393\">Sabri, M.A., &amp; Saber-Ayad, M.M. (2023). <em class=\"reference-title\">MAO Inhibitors.</em> In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK557395/?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">National Library of Medicine</a>.</li><li id=\"use-monoamine-oxidase-inhibitors-primary-care\" value=\"2\" data-reference-number=\"2\" data-reference-format=\"393\">Culpepper, L. (2012). <em class=\"reference-title\">The Use of Monoamine Oxidase Inhibitors in Primary Care.</em> Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. <a href=\"https://www.psychiatrist.com/jcp/monoamine-oxidase-inhibitors-primary-care-2/?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">psychiatrist.com</a>. Accessed October 10 2026.</li><li id=\"depression-medicines\" value=\"3\" data-reference-number=\"3\" data-reference-format=\"393\">US Food &amp; Drug Administration. (2019). <em class=\"reference-title\">Depression Medicines.</em> FDA. <a href=\"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">U.S. Food and Drug Administration</a>. Accessed October 10 2026.</li><li id=\"nardil-phenelzine-sulfate-tablets-usp-fda\" value=\"4\" data-reference-number=\"4\" data-reference-format=\"393\">Parke-Davis, Pfizer, Inc. (2007). <em class=\"reference-title\">Nardil (Phenelzine Sulfate Tablets, USP).FDA.</em> <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011909s038lbl.pdf?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">U.S. Food and Drug Administration</a>. Accessed October 10 2026.</li><li id=\"atypical-depression\" value=\"5\" data-reference-number=\"5\" data-reference-format=\"393\">Singh, T., &amp; Williams, K. (2006). <em class=\"reference-title\">Atypical Depression.</em> Psychiatry (Edgmont (Pa.: Township)), 3(4), 33–39. National Library of Medicine. <a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2990566/?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">PubMed Central</a>. Accessed November 19 2022.</li><li id=\"medications-parkinson-s\" value=\"6\" data-reference-number=\"6\" data-reference-format=\"393\">American Parkinson Disease Association. (2023). <em class=\"reference-title\">Medications for Parkinson's.</em> APDA. <a href=\"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/medication/?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">apdaparkinson.org</a>. Accessed October 10 2026.</li><li id=\"zelapar-selegiline-hydrochloride-orally-disintegrating-tablets\" value=\"7\" data-reference-number=\"7\" data-reference-format=\"393\">Valeant Pharmaceuticals North America. (2008). <em class=\"reference-title\">Zelapar (Selegiline Hydrochloride) Orally Disintegrating Tablets.</em> <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021479s003s004lbl.pdf?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">U.S. Food and Drug Administration</a>. Accessed October 10 2026.</li><li id=\"purves-d-augustine-g-j-fitzpatrick-d-katz-l\" value=\"8\" data-reference-number=\"8\" data-reference-format=\"393\">The Biogenic Amines. (2001). <em class=\"reference-title\">In Purves, D., Augustine, G.J., Fitzpatrick, D., Katz, L.C., LaMantia, A-S., McNamara, J.O., &amp; Williams, S.M.</em> (Eds.) Neuroscience, 2nd Edition. Sunderland, MA: Sinauer Associates. <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK11035/?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">National Library of Medicine</a>.</li><li id=\"inhibitors-mao-mao-b-psychiatry-neurology\" value=\"9\" data-reference-number=\"9\" data-reference-format=\"393\">Finberg, J.P., &amp; Rabey, J.M. (2016). <em class=\"reference-title\">Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.</em> Frontiers in Pharmacology, 7, 340. <a href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2016.00340/full?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">Frontiers</a>. Accessed October 10 2026.</li><li id=\"emsam-selegiline-transdermal-system-fda\" value=\"10\" data-reference-number=\"10\" data-reference-format=\"393\">Somerset Pharmaceuticals Inc. (2014). <em class=\"reference-title\">Emsam (Selegiline Transdermal System).FDA.</em> <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021336s005s010,021708s000lbl.pdf?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">U.S. Food and Drug Administration</a>. Accessed October 10 2026.</li><li id=\"withdrawal-effects-antidepressants\" value=\"11\" data-reference-number=\"11\" data-reference-format=\"393\">Mind. (2020). <em class=\"reference-title\">Withdrawal Effects of Antidepressants.</em> Mind. <a href=\"https://www.mind.org.uk/information-support/drugs-and-treatments/antidepressants/withdrawal-effects-of-antidepressants/?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">Mind</a>. Accessed October 10 2026.</li><li id=\"depression-adults\" value=\"12\" data-reference-number=\"12\" data-reference-format=\"393\">National Health Service. (2023). <em class=\"reference-title\">Depression in Adults.</em> NHS. <a href=\"https://www.nhs.uk/mental-health/conditions/depression-in-adults/?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">NHS</a>. Accessed October 10 2026.</li><li id=\"self-care-depression\" value=\"13\" data-reference-number=\"13\" data-reference-format=\"393\">Mind. (2023). <em class=\"reference-title\">Self-Care for Depression.</em> Mind. <a href=\"https://www.mind.org.uk/information-support/types-of-mental-health-problems/depression/self-care/?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">Mind</a>. Accessed October 10 2026.</li><li id=\"treatment-options-parkinson-s\" value=\"14\" data-reference-number=\"14\" data-reference-format=\"393\">American Parkinson Disease Association. (2023). <em class=\"reference-title\">Treatment Options for Parkinson's.</em> APDA. <a href=\"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-maois&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">apdaparkinson.org</a>. Accessed October 10 2026.</li></ol></section><section class=\"article-medical article-panel\"><h2 id=\"medical-content\">Medical Content</h2><p><a href=\"https://www.mentalhealth.com/clinical-affairs\">The Clinical Affairs Team</a> at MentalHealth.com is a dedicated group of medical professionals with diverse and extensive clinical experience. They actively contribute to the development of content, products, and services, and meticulously review all medical material before publication to ensure accuracy and alignment with current research and conversations in mental health. For more information, please visit the <a href=\"https://www.mentalhealth.com/publishing/editorial-policy\">Editorial Policy</a>.</p></section><section class=\"article-about article-panel\"><h2 id=\"about-mentalhealth-com\">About MentalHealth.com</h2><p>MentalHealth.com helps people understand themselves, build healthier relationships, and access the right care. We bring together mental health education, diagnostics, and care management to support well-being throughout every phase of life.</p><div class=\"article-contributors\"><section class=\"article-bio\"><a href=\"https://www.mentalhealth.com/people/naomi-carr\" class=\"card-identity-photo\" aria-label=\"Naomi Carr\"><img alt=\"\" height=\"64\" loading=\"lazy\" src=\"https://www.mentalhealth.com/assets/optimized/47686b37ff1465ff6711c0b5.jpg\" width=\"64\" decoding=\"async\"></a><div><p class=\"article-bio-role\">Author</p><h3 id=\"naomi-carr\"><a href=\"https://www.mentalhealth.com/people/naomi-carr\">Naomi Carr</a></h3><p class=\"article-bio-credentials\">Writer</p><p>Naomi Carr is a writer with a background in English Literature from Oxford Brookes University.</p><dl><div><dt>Published</dt><dd><time datetime=\"2023-09-11T12:01:21Z\">September 11, 2023</time></dd></div><div><dt>Updated</dt><dd><time datetime=\"2025-08-24T20:06:42Z\">August 24, 2025</time></dd></div></dl></div></section><section class=\"article-bio\"><a href=\"https://www.mentalhealth.com/people/morgan-blair\" class=\"card-identity-photo\" aria-label=\"Morgan Blair, M.A.\"><img alt=\"\" height=\"64\" loading=\"lazy\" src=\"https://www.mentalhealth.com/assets/optimized/9f1be5c5cc2b412cfab5f6cc.jpg\" width=\"64\" decoding=\"async\"></a><div><p class=\"article-bio-role\">Medical Reviewer</p><h3 id=\"morgan-blair\"><a href=\"https://www.mentalhealth.com/people/morgan-blair\">Morgan Blair, M.A.</a></h3><p class=\"article-bio-credentials\">MA, LPCC</p><p>Morgan Blair is a licensed therapist, writer and medical reviewer, holding a master’s degree in clinical mental health counseling from Northwestern University.</p><dl><div><dt>Reviewed</dt><dd><time datetime=\"2023-09-11\">September 11, 2023</time></dd></div></dl></div></section></div></section><section aria-label=\"Related community\" class=\"article-topic-community article-topic-community-end\"><a href=\"https://www.mentalhealth.com/community/medications\" class=\"card-identity-photo\" aria-label=\"Medications\"><img alt=\"\" class=\"topic-community-banner\" height=\"675\" loading=\"lazy\" src=\"https://www.mentalhealth.com/assets/optimized/f5e91a4297495afdb6431ec9.webp\" width=\"1199\" decoding=\"async\"></a><p class=\"topic-community-label\">Related community</p><h2><a href=\"https://www.mentalhealth.com/community/medications\">Medications</a></h2><p>Explore questions and perspectives about psychiatric medications and the treatment experience.</p></section></div></div><aside aria-label=\"Article navigation and related information\" class=\"article-sidebar\" data-bounded-rail=\"\" tabindex=\"0\"><details class=\"article-contents\" data-expanded=\"false\" data-scrolled-past=\"false\" data-section-preview=\"3\" open=\"\"><summary><strong>Table of contents</strong><span aria-hidden=\"true\"></span><small data-current-section=\"\">Choose a section</small></summary><nav aria-label=\"Article contents\"><ol id=\"article-section-list\"><li><a aria-label=\"What are MAOIs?\" href=\"https://www.mentalhealth.com/library/maois#what-are-maois\" title=\"What are MAOIs?\">What are MAOIs?</a></li><li><a aria-label=\"What are MAOIs used to treat?\" href=\"https://www.mentalhealth.com/library/maois#what-are-maois-used-to-treat\" title=\"What are MAOIs used to treat?\">What are MAOIs used to treat?</a></li><li><a aria-label=\"How do MAOIs work?\" href=\"https://www.mentalhealth.com/library/maois#how-do-maois-work\" title=\"How do MAOIs work?\">How do MAOIs work?</a></li><li><a aria-label=\"Types of MAOIs\" href=\"https://www.mentalhealth.com/library/maois#types-of-maois\" title=\"Types of MAOIs\">Types of MAOIs</a></li><li><a aria-label=\"Side effects of MAOIs\" href=\"https://www.mentalhealth.com/library/maois#side-effects-of-maois\" title=\"Side effects of MAOIs\">Side effects of MAOIs</a></li><li><a aria-label=\"Possible interactions with MAOIs\" href=\"https://www.mentalhealth.com/library/maois#possible-interactions-with-maois\" title=\"Possible interactions with MAOIs\">Possible interactions with MAOIs</a></li><li><a aria-label=\"Alternatives to MAOIs\" href=\"https://www.mentalhealth.com/library/maois#alternatives-to-maois\" title=\"Alternatives to MAOIs\">Alternatives to MAOIs</a></li></ol><button aria-controls=\"article-section-list\" aria-expanded=\"false\" class=\"article-sections-toggle\" data-sections-toggle=\"\" type=\"button\">View more</button></nav></details></aside></div></div></div>","text":"Home Library Medications Monoamine Oxidase Inhibitors (MAOIs) Monoamine Oxidase Inhibitors (MAOIs) Written by Naomi CarrMedically reviewed by Morgan Blair, M.A. Published on September 11, 2023 · Updated on August 24, 2025 Monoamine oxidase inhibitors, or MAOIs, are a type of antidepressant medication used to treat mental health and neurological conditions. MAOIs are no longer a first choice in treating depression unless in specific and necessary circumstances due to their potential risks. Alternative medications and treatments are available if required. Key takeaways MAOIs reduce the breakdown of certain neurotransmitters and are used for selected depressive and neurological conditions. They are generally not first-choice antidepressants because of side effects and interaction risks. Medication combinations and tyramine-containing foods can cause serious reactions, requiring careful prescribing and dietary guidance. What are MAOIs? Monoamine oxidase inhibitors (MAOIs) are a type of antidepressant medication. They were the first antidepressants developed in the 1950s and are still used today to treat depressive disorders and neurological conditions⁠[1]. MAOIs can cause various side effects, dietary restrictions, and health risks, so they are not typically used as a first-line treatment but are still used in necessary circumstances, as they can be effective treatments⁠[2]. What are MAOIs used to treat? The FDA has approved some MAOIs to treat major depressive disorder⁠[3]. It is advised not to use MAOIs as a first-line treatment for depression due to their potential risks. However, MAOIs may be the preferred treatment for treatment-resistant depression or atypical depression, with symptoms such as anxiety, increased sleep, or changes in appetite⁠[4][5]. Other MAOIs have been FDA-approved for use in treating Parkinson’s disease. They may be used alone or alongside levodopa, a commonly used medication for Parkinson’s, and help to reduce motor symptoms⁠[6][7]. MAOIs are occasionally used off-label for uses that are not FDA-approved. This includes⁠[1][8]: Depressive episodes in bipolar disorder Anxiety disorders, particularly social phobia and panic disorder Attention-deficit/hyperactivity disorder (ADHD) Narcolepsy How do MAOIs work? Monoamine oxidase is an enzyme in the brain responsible for degrading and regulating several neurotransmitters, including serotonin, dopamine, and norepinephrine. These neurotransmitters are known as amine neurotransmitters and help regulate several functions, including mood, behavior, energy, cognition, and sleep⁠[1][9]. MAO inhibitors prevent the monoamine oxidase enzyme from breaking down these neurotransmitters, thereby increasing their levels. Reduced levels of amine neurotransmitters, particularly serotonin, are known to be involved in the development of depression, so by increasing these levels, MAOIs cause an antidepressant effect⁠[10]. There are two types of monoamine oxidase enzymes, called MAO-A and MAO-B. MAO-A impacts serotonin, dopamine, and norepinephrine. In contrast, MAO-B does not impact serotonin but also affects dopamine and norepinephrine⁠[1]. There are three types of MAOIs: ones that selectively inhibit MAO-A, ones that selectively inhibit MAO-B, and ones that are not selective, thus inhibiting both MAO-A and MAO-B. As such, each of these MAOIs can cause different effects, with those that inhibit MAO-A having a more substantial antidepressant effect than those that only inhibit MAO-B⁠[10]. However, as MAO-A also metabolizes dietary tyramine, MAO-A inhibitors prevent this from occurring, allowing tyramine to enter the bloodstream. This triggers the release of norepinephrine, which results in an increase in blood pressure and a hypertensive crisis, commonly referred to as the ‘cheese effect’⁠[2][10]. Most MAOIs are administered as an oral tablet, which enters the gastrointestinal tract. But a transdermal patch has been developed to provide the antidepressant effects of MAOIs while preventing the ‘cheese effect’, as the medication is absorbed directly into the bloodstream⁠[2][11]. Types of MAOIs There are various types of MAOIs, categorized as MAO-A inhibitors, MAO-B inhibitors, and nonselective MAOIs⁠[3][6][10]: MAO-A inhibitors Clorgyline: Clorgyline is not used clinically. Moclobemide: Moclobemide is not approved for use in the US but is used in other parts of the world for depression and social phobia. MAO-B inhibitors Selegiline: Selegiline is FDA-approved in the treatment of Parkinson’s disease. It is available as an oral tablet to be swallowed whole under the brand names L-deprenyl and Eldepryl. It is also available as an orally disintegrating tablet under the brand name Zelapar. Rasagiline: Rasagiline is FDA-approved for treating Parkinson’s disease. It is available as a tablet under the brand name Azilect. Safinamide: Safinamide is FDA-approved for treating Parkinson’s disease. It is available as a tablet under the brand name Xadago. Nonselective MAOIs Phenelzine: Phenelzine is FDA-approved for the treatment of depression. It is available as a tablet under the brand name Nardil. Tranylcypromine: Tranylcypromine is FDA-approved for the treatment of depression. It is available as a tablet under the brand name Parnate. Isocarboxazid: Isocarboxazid is FDA-approved to treat depression. It is available as a tablet under the brand name Marplan. Transdermal Selegiline: Transdermal selegiline is FDA-approved to treat depression. It is available as a skin patch under the brand name Emsam. Side effects of MAOIs Common short-term side effects of MAOIs include⁠[2][3][6]: Nausea Drowsiness Dizziness Insomnia Stomach upset, including diarrhea and constipation Increased suicidal ideation: This risk is higher in people under the age of 24 and within the first few weeks or months of a new treatment. If you notice emerging or increasing thoughts of self-harm or suicide when commencing MAOI treatment, inform your doctor or mental health professional immediately. Possible side effects of long-term MAOI use include⁠[2][4]: Weight gain Sexual dysfunction Muscle pain Muscle spasms Numbness and tingling Difficulty passing urine MAOI withdrawal symptoms can occur when abruptly stopping the medication. This can include⁠[1][12]: Nausea Vomiting Fatigue Agitation Irritability Insomnia Psychotic symptoms such as delusions and hallucinations To prevent withdrawal, your doctor will likely reduce your dose gradually. It is important not to suddenly stop MAOI treatment, as this can increase the risk of withdrawal symptoms. Possible interactions with MAOIs Serotonin syndrome MAOIs can contribute to the onset of serotonin syndrome if used alongside other antidepressants or medications that increase serotonin. Dangerously high serotonin levels can cause serotonin syndrome and can, in some cases, be fatal. Symptoms of serotonin syndrome include⁠[2][11]: Fatigue Change in mental state Hallucinations Stomach pain Diarrhea Kidney failure Shaking Irregular heartbeat Fever Sweating It is advised not to use MAOIs while using SSRIs, SNRIs, TCAs, other MAOIs, bupropion, and amphetamines. When changing between one of these medications and an MAOI, it is advised to wait at least 14 days between the last dose of the previous medication and the first dose of the next. For medicines with longer half-lives, such as fluoxetine, it is necessary to wait longer⁠[2]. ‘Cheese effect’ The hypertensive crisis that MAOIs can cause is often called the ‘cheese effect’. It is caused by the impact MAOIs have on tyramine metabolization in the intestines. The ‘cheese effect’ can cause severe and potentially fatal issues, including⁠[4][10]: Increased blood pressure Headaches Irregular or fast heartbeat Nausea Stroke As such, it is required to follow a restricted diet when taking an MAOI to help prevent this. Foods high in tyramine should be avoided or limited, such as⁠[2]: Soy products Certain cheeses Bananas Certain types of meat and fish Broad bean pods Dietary restrictions are not necessary when taking MAO-B inhibitors or the MAOI transdermal patch in a low dose, as these types of MAOIs are not likely to cause this effect. Drug interactions Some medications can also cause a hypertensive crisis when combined with MAOIs and should be avoided. This includes⁠[1][2]: Parkinson’s medications Medications that increase dopamine, serotonin, or epinephrine Stimulants Amphetamines Opioids Tryptophan Vasoconstrictors Always inform your doctor of all medications you take, whether prescribed or over the counter, before starting a new treatment. Precautions People with heart, liver, or kidney conditions may not be able to take MAOIs safely. It is advised to inform your doctor of any existing conditions before starting MAOI treatment, as it may be unsafe to do so, or your doctor may wish to prescribe you a reduced dose and ensure careful monitoring of your physical health⁠[4]. Alternatives to MAOIs Before being prescribed MAOIs, your doctor will likely try an alternative medication that carries fewer risks. Alternative medications for depression Several other antidepressant medications are available that will likely be prescribed before trying an MAOI. This includes⁠[3][13]: Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline, and citalopram Serotonin and norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine, duloxetine, and levomilnacipran Tricyclic antidepressants (TCAs), such as imipramine, amitriptyline, and desipramine Atypical antidepressants, such as mirtazapine and bupropion Subject matter expert Leila Khurshid, Pharm.D. Clinical pharmacy and medication View profile Alternative treatment for depression Alongside antidepressant medication, utilizing therapy and self-help techniques is often very helpful. Available therapies that can be effective at managing symptoms of depression include⁠[13]: Cognitive behavioral therapy (CBT) Interpersonal therapy (IPT) Psychodynamic therapy Mindfulness-based therapy Behavioral activation Family therapy Self-help techniques that can be beneficial for managing symptoms of depression include⁠[13][14]: Talking to others Keeping a mood diary Relaxation techniques Mindfulness Avoiding drugs and alcohol Spending time outside in nature Improving physical health, such as eating a healthy diet, regularly exercising, and following a sleep schedule Alternative medications for Parkinson’s disease Many alternative medications can be used to treat Parkinson’s disease, which can be used alongside or instead of MAOIs. This includes⁠[6]: Dopamine precursors, such as levodopa Dopamine agonists, such as pramipexole and ropinirole Anticholinergics, such as benztropine and trihexyphenidyl Additional treatments for Parkinson’s disease include⁠[14]: Speech therapy Physical therapy Occupational therapy Deep brain stimulation (DBS) References Sabri, M.A., & Saber-Ayad, M.M. (2023). MAO Inhibitors. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine. Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026. US Food & Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026. Parke-Davis, Pfizer, Inc. (2007). Nardil (Phenelzine Sulfate Tablets, USP).FDA. U.S. Food and Drug Administration. Accessed October 10 2026. Singh, T., & Williams, K. (2006). Atypical Depression. Psychiatry (Edgmont (Pa.: Township)), 3(4), 33–39. National Library of Medicine. PubMed Central. Accessed November 19 2022. American Parkinson Disease Association. (2023). Medications for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026. Valeant Pharmaceuticals North America. (2008). Zelapar (Selegiline Hydrochloride) Orally Disintegrating Tablets. U.S. Food and Drug Administration. Accessed October 10 2026. The Biogenic Amines. (2001). In Purves, D., Augustine, G.J., Fitzpatrick, D., Katz, L.C., LaMantia, A-S., McNamara, J.O., & Williams, S.M. (Eds.) Neuroscience, 2nd Edition. Sunderland, MA: Sinauer Associates. National Library of Medicine. Finberg, J.P., & Rabey, J.M. (2016). Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Frontiers in Pharmacology, 7, 340. Frontiers. Accessed October 10 2026. Somerset Pharmaceuticals Inc. (2014). Emsam (Selegiline Transdermal System).FDA. U.S. Food and Drug Administration. Accessed October 10 2026. Mind. (2020). Withdrawal Effects of Antidepressants. Mind. Mind. Accessed October 10 2026. National Health Service. (2023). Depression in Adults. NHS. NHS. Accessed October 10 2026. Mind. (2023). Self-Care for Depression. Mind. Mind. Accessed October 10 2026. American Parkinson Disease Association. (2023). Treatment Options for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026. Medical Content The Clinical Affairs Team at MentalHealth.com is a dedicated group of medical professionals with diverse and extensive clinical experience. They actively contribute to the development of content, products, and services, and meticulously review all medical material before publication to ensure accuracy and alignment with current research and conversations in mental health. For more information, please visit the Editorial Policy. About MentalHealth.com MentalHealth.com helps people understand themselves, build healthier relationships, and access the right care. We bring together mental health education, diagnostics, and care management to support well-being throughout every phase of life. Author Naomi Carr Writer Naomi Carr is a writer with a background in English Literature from Oxford Brookes University. Published September 11, 2023 Updated August 24, 2025 Medical Reviewer Morgan Blair, M.A. MA, LPCC Morgan Blair is a licensed therapist, writer and medical reviewer, holding a master’s degree in clinical mental health counseling from Northwestern University. Reviewed September 11, 2023 Related community Medications Explore questions and perspectives about psychiatric medications and the treatment experience. Table of contentsChoose a section What are MAOIs? What are MAOIs used to treat? How do MAOIs work? Types of MAOIs Side effects of MAOIs Possible interactions with MAOIs Alternatives to MAOIs View more","wordCount":1997},"schema":{"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://www.mentalhealth.com/#organization","name":"MentalHealth.com","url":"https://www.mentalhealth.com/","publishingPrinciples":"https://www.mentalhealth.com/publishing/editorial-policy"},{"@type":"WebSite","@id":"https://www.mentalhealth.com/#website","url":"https://www.mentalhealth.com/","name":"MentalHealth.com","inLanguage":"en-US","publisher":{"@id":"https://www.mentalhealth.com/#organization"}},{"@type":"BreadcrumbList","@id":"https://www.mentalhealth.com/library/maois#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.mentalhealth.com/"},{"@type":"ListItem","position":2,"name":"Library","item":"https://www.mentalhealth.com/library"},{"@type":"ListItem","position":3,"name":"Medications","item":"https://www.mentalhealth.com/library/medications"},{"@type":"ListItem","position":4,"name":"Monoamine Oxidase Inhibitors (MAOIs)","item":"https://www.mentalhealth.com/library/maois"}]},{"@type":"ImageObject","@id":"https://www.mentalhealth.com/library/maois#primaryimage","url":"https://www.mentalhealth.com/assets/optimized/8debdbe7c5f9c329801a75ed.webp","contentUrl":"https://www.mentalhealth.com/assets/optimized/8debdbe7c5f9c329801a75ed.webp","width":1200,"height":630,"encodingFormat":"image/webp","caption":"A healthcare professional rests a reassuring hand on a patient's knee."},{"@type":"Person","@id":"https://www.mentalhealth.com/people/naomi-carr#person","name":"Naomi Carr","url":"https://www.mentalhealth.com/people/naomi-carr","jobTitle":"Writer","image":"https://www.mentalhealth.com/assets/optimized/47686b37ff1465ff6711c0b5.jpg","sameAs":["https://www.linkedin.com/in/naomi-carr-07784590/"],"memberOf":[{"@id":"https://www.mentalhealth.com/publishing#department"}]},{"@type":"Person","@id":"https://www.mentalhealth.com/people/morgan-blair#person","name":"Morgan Blair","url":"https://www.mentalhealth.com/people/morgan-blair","jobTitle":"MA, LPCC","image":"https://www.mentalhealth.com/assets/optimized/9f1be5c5cc2b412cfab5f6cc.jpg","sameAs":["https://www.linkedin.com/in/morgan-blair-5627aa88/"],"memberOf":[{"@id":"https://www.mentalhealth.com/clinical-affairs#department"}]},{"@type":"Article","@id":"https://www.mentalhealth.com/library/maois#article","url":"https://www.mentalhealth.com/library/maois","headline":"Monoamine Oxidase Inhibitors (MAOIs)","description":"Monoamine oxidase inhibitors, commonly referred to as MAOIs, are a type of antidepressant medication used to treat a range of mental health conditions.","wordCount":1493,"mainEntityOfPage":{"@id":"https://www.mentalhealth.com/library/maois#webpage"},"publisher":{"@id":"https://www.mentalhealth.com/#organization"},"articleSection":"Medications","citation":[{"@type":"CreativeWork","name":"Sabri, M.A., & Saber-Ayad, M.M. (2023). MAO Inhibitors. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine.","url":"https://www.ncbi.nlm.nih.gov/books/NBK557395/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.","url":"https://www.psychiatrist.com/jcp/monoamine-oxidase-inhibitors-primary-care-2/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"US Food & Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Parke-Davis, Pfizer, Inc. (2007). Nardil (Phenelzine Sulfate Tablets, USP).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011909s038lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Singh, T., & Williams, K. (2006). Atypical Depression. Psychiatry (Edgmont (Pa.: Township)), 3(4), 33–39. National Library of Medicine. PubMed Central. Accessed November 19 2022.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2990566/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"American Parkinson Disease Association. (2023). Medications for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.","url":"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/medication/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Valeant Pharmaceuticals North America. (2008). Zelapar (Selegiline Hydrochloride) Orally Disintegrating Tablets. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021479s003s004lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"The Biogenic Amines. (2001). In Purves, D., Augustine, G.J., Fitzpatrick, D., Katz, L.C., LaMantia, A-S., McNamara, J.O., & Williams, S.M. (Eds.) Neuroscience, 2nd Edition. Sunderland, MA: Sinauer Associates. National Library of Medicine.","url":"https://www.ncbi.nlm.nih.gov/books/NBK11035/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Finberg, J.P., & Rabey, J.M. (2016). Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Frontiers in Pharmacology, 7, 340. Frontiers. Accessed October 10 2026.","url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2016.00340/full?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Somerset Pharmaceuticals Inc. (2014). Emsam (Selegiline Transdermal System).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021336s005s010,021708s000lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Mind. (2020). Withdrawal Effects of Antidepressants. Mind. Mind. Accessed October 10 2026.","url":"https://www.mind.org.uk/information-support/drugs-and-treatments/antidepressants/withdrawal-effects-of-antidepressants/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"National Health Service. (2023). Depression in Adults. NHS. NHS. Accessed October 10 2026.","url":"https://www.nhs.uk/mental-health/conditions/depression-in-adults/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Mind. (2023). Self-Care for Depression. Mind. Mind. Accessed October 10 2026.","url":"https://www.mind.org.uk/information-support/types-of-mental-health-problems/depression/self-care/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"American Parkinson Disease Association. (2023). Treatment Options for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.","url":"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"}],"inLanguage":"en-US","author":[{"@id":"https://www.mentalhealth.com/people/naomi-carr#person"}],"image":{"@id":"https://www.mentalhealth.com/library/maois#primaryimage"},"about":{"@type":"Thing","@id":"https://www.mentalhealth.com/library/medications#topic","name":"Medications"},"datePublished":"2023-09-11T12:01:21Z","dateModified":"2025-08-24T20:06:42Z"},{"@type":"MedicalWebPage","@id":"https://www.mentalhealth.com/library/maois#webpage","url":"https://www.mentalhealth.com/library/maois","name":"Monoamine Oxidase Inhibitors (MAOIs)","description":"Monoamine oxidase inhibitors, commonly referred to as MAOIs, are a type of antidepressant medication used to treat a range of mental health conditions.","inLanguage":"en-US","isPartOf":{"@id":"https://www.mentalhealth.com/library/medications#webpage"},"breadcrumb":{"@id":"https://www.mentalhealth.com/library/maois#breadcrumb"},"mainEntity":{"@id":"https://www.mentalhealth.com/library/maois#article"},"relatedLink":["https://www.mentalhealth.com/library/antidepressants","https://www.mentalhealth.com/library/antiparkinson-agents","https://www.mentalhealth.com/library/molindone-uses-side-effects-interactions","https://www.mentalhealth.com/library/opioids","https://www.mentalhealth.com/library/amphetamines","https://www.mentalhealth.com/people/leila-khurshid"],"publisher":{"@id":"https://www.mentalhealth.com/#organization"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"General public"},"primaryImageOfPage":{"@id":"https://www.mentalhealth.com/library/maois#primaryimage"},"image":{"@id":"https://www.mentalhealth.com/library/maois#primaryimage"},"reviewedBy":{"@id":"https://www.mentalhealth.com/people/morgan-blair#person"},"about":{"@type":"Thing","@id":"https://www.mentalhealth.com/library/medications#topic","name":"Medications"},"citation":[{"@type":"CreativeWork","name":"Sabri, M.A., & Saber-Ayad, M.M. (2023). MAO Inhibitors. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine.","url":"https://www.ncbi.nlm.nih.gov/books/NBK557395/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.","url":"https://www.psychiatrist.com/jcp/monoamine-oxidase-inhibitors-primary-care-2/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"US Food & Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Parke-Davis, Pfizer, Inc. (2007). Nardil (Phenelzine Sulfate Tablets, USP).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011909s038lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Singh, T., & Williams, K. (2006). Atypical Depression. Psychiatry (Edgmont (Pa.: Township)), 3(4), 33–39. National Library of Medicine. PubMed Central. Accessed November 19 2022.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2990566/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"American Parkinson Disease Association. (2023). Medications for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.","url":"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/medication/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Valeant Pharmaceuticals North America. (2008). Zelapar (Selegiline Hydrochloride) Orally Disintegrating Tablets. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021479s003s004lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"The Biogenic Amines. (2001). In Purves, D., Augustine, G.J., Fitzpatrick, D., Katz, L.C., LaMantia, A-S., McNamara, J.O., & Williams, S.M. (Eds.) Neuroscience, 2nd Edition. Sunderland, MA: Sinauer Associates. National Library of Medicine.","url":"https://www.ncbi.nlm.nih.gov/books/NBK11035/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Finberg, J.P., & Rabey, J.M. (2016). Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Frontiers in Pharmacology, 7, 340. Frontiers. Accessed October 10 2026.","url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2016.00340/full?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Somerset Pharmaceuticals Inc. (2014). Emsam (Selegiline Transdermal System).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021336s005s010,021708s000lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Mind. (2020). Withdrawal Effects of Antidepressants. Mind. Mind. Accessed October 10 2026.","url":"https://www.mind.org.uk/information-support/drugs-and-treatments/antidepressants/withdrawal-effects-of-antidepressants/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"National Health Service. (2023). Depression in Adults. NHS. NHS. Accessed October 10 2026.","url":"https://www.nhs.uk/mental-health/conditions/depression-in-adults/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Mind. (2023). Self-Care for Depression. Mind. Mind. Accessed October 10 2026.","url":"https://www.mind.org.uk/information-support/types-of-mental-health-problems/depression/self-care/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"American Parkinson Disease Association. (2023). Treatment Options for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.","url":"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"}],"datePublished":"2023-09-11T12:01:21Z","dateModified":"2025-08-24T20:06:42Z","lastReviewed":"2023-09-11"}]},"representations":{"html":"https://www.mentalhealth.com/library/maois","json":"https://www.mentalhealth.com/data/library/maois.json","jsonLd":"https://www.mentalhealth.com/data/library/maois.ld.json"},"$schema":"https://www.mentalhealth.com/data/page.schema.json","images":[{"url":"https://www.mentalhealth.com/assets/optimized/8debdbe7c5f9c329801a75ed.webp","alt":"A healthcare professional rests a reassuring hand on a patient's knee.","width":1200,"height":630},{"url":"https://www.mentalhealth.com/assets/optimized/90339bb61ace127cee8df5f2.webp","alt":"","width":64,"height":64},{"url":"https://www.mentalhealth.com/assets/optimized/47686b37ff1465ff6711c0b5.jpg","alt":"","width":64,"height":64},{"url":"https://www.mentalhealth.com/assets/optimized/9f1be5c5cc2b412cfab5f6cc.jpg","alt":"","width":64,"height":64},{"url":"https://www.mentalhealth.com/assets/optimized/f5e91a4297495afdb6431ec9.webp","alt":"","width":1199,"height":675}],"sections":[{"id":"key-takeaways","title":"Key takeaways","level":2,"url":"https://www.mentalhealth.com/library/maois#key-takeaways"},{"id":"what-are-maois","title":"What are MAOIs?","level":2,"url":"https://www.mentalhealth.com/library/maois#what-are-maois"},{"id":"what-are-maois-used-to-treat","title":"What are MAOIs used to treat?","level":2,"url":"https://www.mentalhealth.com/library/maois#what-are-maois-used-to-treat"},{"id":"how-do-maois-work","title":"How do MAOIs work?","level":2,"url":"https://www.mentalhealth.com/library/maois#how-do-maois-work"},{"id":"types-of-maois","title":"Types of MAOIs","level":2,"url":"https://www.mentalhealth.com/library/maois#types-of-maois"},{"id":"mao-a-inhibitors","title":"MAO-A inhibitors","level":3,"url":"https://www.mentalhealth.com/library/maois#mao-a-inhibitors"},{"id":"mao-b-inhibitors","title":"MAO-B inhibitors","level":3,"url":"https://www.mentalhealth.com/library/maois#mao-b-inhibitors"},{"id":"nonselective-maois","title":"Nonselective MAOIs","level":3,"url":"https://www.mentalhealth.com/library/maois#nonselective-maois"},{"id":"side-effects-of-maois","title":"Side effects of MAOIs","level":2,"url":"https://www.mentalhealth.com/library/maois#side-effects-of-maois"},{"id":"possible-interactions-with-maois","title":"Possible interactions with MAOIs","level":2,"url":"https://www.mentalhealth.com/library/maois#possible-interactions-with-maois"},{"id":"serotonin-syndrome-maois-can-contribute-to-the-onset-of-serotonin-syndrome-if-used-alongside-other-antidepressants-or-medications-that-increase-serotonin-dangerously-high-serotonin-levels-can-cause-serotonin-syndrome-and-can-in-some-cases-be-fatal-symptoms-of-serotonin-syndrome-include","title":"Serotonin syndrome","level":3,"url":"https://www.mentalhealth.com/library/maois#serotonin-syndrome-maois-can-contribute-to-the-onset-of-serotonin-syndrome-if-used-alongside-other-antidepressants-or-medications-that-increase-serotonin-dangerously-high-serotonin-levels-can-cause-serotonin-syndrome-and-can-in-some-cases-be-fatal-symptoms-of-serotonin-syndrome-include"},{"id":"cheese-effect-the-hypertensive-crisis-that-maois-can-cause-is-often-called-the-cheese-effect-it-is-caused-by-the-impact-maois-have-on-tyramine-metabolization-in-the-intestines-the-cheese-effect-can-cause-severe-and-potentially-fatal-issues-including","title":"‘Cheese effect’","level":3,"url":"https://www.mentalhealth.com/library/maois#cheese-effect-the-hypertensive-crisis-that-maois-can-cause-is-often-called-the-cheese-effect-it-is-caused-by-the-impact-maois-have-on-tyramine-metabolization-in-the-intestines-the-cheese-effect-can-cause-severe-and-potentially-fatal-issues-including"},{"id":"drug-interactions-some-medications-can-also-cause-a-hypertensive-crisis-when-combined-with-maois-and-should-be-avoided-this-includes","title":"Drug interactions","level":3,"url":"https://www.mentalhealth.com/library/maois#drug-interactions-some-medications-can-also-cause-a-hypertensive-crisis-when-combined-with-maois-and-should-be-avoided-this-includes"},{"id":"precautions-people-with-heart-liver-or-kidney-conditions-may-not-be-able-to-take-maois-safely-it-is-advised-to-inform-your-doctor-of-any-existing-conditions-before-starting-maoi-treatment-as-it-may-be-unsafe-to-do-so-or-your-doctor-may-wish-to-prescribe-you-a-reduced-dose-and-ensure-careful-monitoring-of-your-physical-health","title":"Precautions","level":3,"url":"https://www.mentalhealth.com/library/maois#precautions-people-with-heart-liver-or-kidney-conditions-may-not-be-able-to-take-maois-safely-it-is-advised-to-inform-your-doctor-of-any-existing-conditions-before-starting-maoi-treatment-as-it-may-be-unsafe-to-do-so-or-your-doctor-may-wish-to-prescribe-you-a-reduced-dose-and-ensure-careful-monitoring-of-your-physical-health"},{"id":"alternatives-to-maois","title":"Alternatives to MAOIs","level":2,"url":"https://www.mentalhealth.com/library/maois#alternatives-to-maois"},{"id":"alternative-medications-for-depression-several-other-antidepressant-medications-are-available-that-will-likely-be-prescribed-before-trying-an-maoi-this-includes","title":"Alternative medications for depression","level":3,"url":"https://www.mentalhealth.com/library/maois#alternative-medications-for-depression-several-other-antidepressant-medications-are-available-that-will-likely-be-prescribed-before-trying-an-maoi-this-includes"},{"id":"alternative-treatment-for-depression-alongside-antidepressant-medication-utilizing-therapy-and-self-help-techniques-is-often-very-helpful-available-therapies-that-can-be-effective-at-managing-symptoms-of-depression-include","title":"Alternative treatment for depression","level":3,"url":"https://www.mentalhealth.com/library/maois#alternative-treatment-for-depression-alongside-antidepressant-medication-utilizing-therapy-and-self-help-techniques-is-often-very-helpful-available-therapies-that-can-be-effective-at-managing-symptoms-of-depression-include"},{"id":"alternative-medications-for-parkinson-s-disease-many-alternative-medications-can-be-used-to-treat-parkinson-s-disease-which-can-be-used-alongside-or-instead-of-maois-this-includes","title":"Alternative medications for Parkinson’s disease","level":3,"url":"https://www.mentalhealth.com/library/maois#alternative-medications-for-parkinson-s-disease-many-alternative-medications-can-be-used-to-treat-parkinson-s-disease-which-can-be-used-alongside-or-instead-of-maois-this-includes"}],"references":[{"number":1,"id":"https://www.mentalhealth.com/library/maois#mao-inhibitors","text":"Sabri, M.A., & Saber-Ayad, M.M. (2023). MAO Inhibitors. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine.","links":[{"url":"https://www.ncbi.nlm.nih.gov/books/NBK557395/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"National Library of Medicine"}],"url":"https://www.ncbi.nlm.nih.gov/books/NBK557395/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":2,"id":"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care","text":"Culpepper, L. (2012). The Use of Monoamine Oxidase Inhibitors in Primary Care. Journal of Clinical Psychiatry, 73(Suppl 1), 37-41. psychiatrist.com. Accessed October 10 2026.","links":[{"url":"https://www.psychiatrist.com/jcp/monoamine-oxidase-inhibitors-primary-care-2/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"psychiatrist.com"}],"url":"https://www.psychiatrist.com/jcp/monoamine-oxidase-inhibitors-primary-care-2/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":3,"id":"https://www.mentalhealth.com/library/maois#depression-medicines","text":"US Food & Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","links":[{"url":"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"}],"url":"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":4,"id":"https://www.mentalhealth.com/library/maois#nardil-phenelzine-sulfate-tablets-usp-fda","text":"Parke-Davis, Pfizer, Inc. (2007). Nardil (Phenelzine Sulfate Tablets, USP).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","links":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011909s038lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"}],"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011909s038lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":5,"id":"https://www.mentalhealth.com/library/maois#atypical-depression","text":"Singh, T., & Williams, K. (2006). Atypical Depression. Psychiatry (Edgmont (Pa.: Township)), 3(4), 33–39. National Library of Medicine. PubMed Central. Accessed November 19 2022.","links":[{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2990566/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"PubMed Central"}],"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2990566/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":6,"id":"https://www.mentalhealth.com/library/maois#medications-parkinson-s","text":"American Parkinson Disease Association. (2023). Medications for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.","links":[{"url":"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/medication/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"apdaparkinson.org"}],"url":"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/medication/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":7,"id":"https://www.mentalhealth.com/library/maois#zelapar-selegiline-hydrochloride-orally-disintegrating-tablets","text":"Valeant Pharmaceuticals North America. (2008). Zelapar (Selegiline Hydrochloride) Orally Disintegrating Tablets. U.S. Food and Drug Administration. Accessed October 10 2026.","links":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021479s003s004lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"}],"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021479s003s004lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":8,"id":"https://www.mentalhealth.com/library/maois#purves-d-augustine-g-j-fitzpatrick-d-katz-l","text":"The Biogenic Amines. (2001). In Purves, D., Augustine, G.J., Fitzpatrick, D., Katz, L.C., LaMantia, A-S., McNamara, J.O., & Williams, S.M. (Eds.) Neuroscience, 2nd Edition. Sunderland, MA: Sinauer Associates. National Library of Medicine.","links":[{"url":"https://www.ncbi.nlm.nih.gov/books/NBK11035/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"National Library of Medicine"}],"url":"https://www.ncbi.nlm.nih.gov/books/NBK11035/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":9,"id":"https://www.mentalhealth.com/library/maois#inhibitors-mao-mao-b-psychiatry-neurology","text":"Finberg, J.P., & Rabey, J.M. (2016). Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Frontiers in Pharmacology, 7, 340. Frontiers. Accessed October 10 2026.","links":[{"url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2016.00340/full?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"Frontiers"}],"url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2016.00340/full?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":10,"id":"https://www.mentalhealth.com/library/maois#emsam-selegiline-transdermal-system-fda","text":"Somerset Pharmaceuticals Inc. (2014). Emsam (Selegiline Transdermal System).FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","links":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021336s005s010,021708s000lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"}],"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021336s005s010,021708s000lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":11,"id":"https://www.mentalhealth.com/library/maois#withdrawal-effects-antidepressants","text":"Mind. (2020). Withdrawal Effects of Antidepressants. Mind. Mind. Accessed October 10 2026.","links":[{"url":"https://www.mind.org.uk/information-support/drugs-and-treatments/antidepressants/withdrawal-effects-of-antidepressants/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"Mind"}],"url":"https://www.mind.org.uk/information-support/drugs-and-treatments/antidepressants/withdrawal-effects-of-antidepressants/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":12,"id":"https://www.mentalhealth.com/library/maois#depression-adults","text":"National Health Service. (2023). Depression in Adults. NHS. NHS. Accessed October 10 2026.","links":[{"url":"https://www.nhs.uk/mental-health/conditions/depression-in-adults/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"NHS"}],"url":"https://www.nhs.uk/mental-health/conditions/depression-in-adults/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":13,"id":"https://www.mentalhealth.com/library/maois#self-care-depression","text":"Mind. (2023). Self-Care for Depression. Mind. Mind. Accessed October 10 2026.","links":[{"url":"https://www.mind.org.uk/information-support/types-of-mental-health-problems/depression/self-care/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"Mind"}],"url":"https://www.mind.org.uk/information-support/types-of-mental-health-problems/depression/self-care/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"},{"number":14,"id":"https://www.mentalhealth.com/library/maois#treatment-options-parkinson-s","text":"American Parkinson Disease Association. (2023). Treatment Options for Parkinson's. APDA. apdaparkinson.org. Accessed October 10 2026.","links":[{"url":"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"apdaparkinson.org"}],"url":"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com"}],"relatedReading":[],"links":[{"url":"https://www.mentalhealth.com/","label":"Home"},{"url":"https://www.mentalhealth.com/library","label":"Library"},{"url":"https://www.mentalhealth.com/library/medications","label":"Medications"},{"url":"https://www.mentalhealth.com/people/naomi-carr","label":"Naomi Carr"},{"url":"https://www.mentalhealth.com/people/morgan-blair","label":"Morgan Blair, M.A."},{"url":"https://www.mentalhealth.com/library/antidepressants","label":"antidepressant medication"},{"url":"https://www.mentalhealth.com/library/maois#mao-inhibitors","label":"[1]"},{"url":"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care","label":"[2]"},{"url":"https://www.mentalhealth.com/library/maois#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/atypical-depression","label":"atypical depression"},{"url":"https://www.mentalhealth.com/library/maois#nardil-phenelzine-sulfate-tablets-usp-fda","label":"[4]"},{"url":"https://www.mentalhealth.com/library/maois#atypical-depression","label":"[5]"},{"url":"https://www.mentalhealth.com/library/maois#medications-parkinson-s","label":"[6]"},{"url":"https://www.mentalhealth.com/library/maois#zelapar-selegiline-hydrochloride-orally-disintegrating-tablets","label":"[7]"},{"url":"https://www.mentalhealth.com/library/maois#mao-inhibitors","label":"[1]"},{"url":"https://www.mentalhealth.com/library/maois#purves-d-augustine-g-j-fitzpatrick-d-katz-l","label":"[8]"},{"url":"https://www.mentalhealth.com/library/bipolar-disorder","label":"bipolar disorder"},{"url":"https://www.mentalhealth.com/library/panic-attacks-in-anxiety-disorders","label":"panic disorder"},{"url":"https://www.mentalhealth.com/library/sleep-disorders","label":"Narcolepsy"},{"url":"https://www.mentalhealth.com/library/maois#mao-inhibitors","label":"[1]"},{"url":"https://www.mentalhealth.com/library/maois#inhibitors-mao-mao-b-psychiatry-neurology","label":"[9]"},{"url":"https://www.mentalhealth.com/library/maois#emsam-selegiline-transdermal-system-fda","label":"[10]"},{"url":"https://www.mentalhealth.com/library/maois#mao-inhibitors","label":"[1]"},{"url":"https://www.mentalhealth.com/library/maois#emsam-selegiline-transdermal-system-fda","label":"[10]"},{"url":"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care","label":"[2]"},{"url":"https://www.mentalhealth.com/library/maois#emsam-selegiline-transdermal-system-fda","label":"[10]"},{"url":"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care","label":"[2]"},{"url":"https://www.mentalhealth.com/library/maois#withdrawal-effects-antidepressants","label":"[11]"},{"url":"https://www.mentalhealth.com/library/maois#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/maois#medications-parkinson-s","label":"[6]"},{"url":"https://www.mentalhealth.com/library/maois#emsam-selegiline-transdermal-system-fda","label":"[10]"},{"url":"https://www.mentalhealth.com/library/moclobemide-uses-dosage-side-effects","label":"Moclobemide"},{"url":"https://www.mentalhealth.com/library/phenelzine-uses-dosage-side-effects","label":"Phenelzine"},{"url":"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care","label":"[2]"},{"url":"https://www.mentalhealth.com/library/maois#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/maois#medications-parkinson-s","label":"[6]"},{"url":"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care","label":"[2]"},{"url":"https://www.mentalhealth.com/library/maois#nardil-phenelzine-sulfate-tablets-usp-fda","label":"[4]"},{"url":"https://www.mentalhealth.com/library/maois#mao-inhibitors","label":"[1]"},{"url":"https://www.mentalhealth.com/library/maois#depression-adults","label":"[12]"},{"url":"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care","label":"[2]"},{"url":"https://www.mentalhealth.com/library/maois#withdrawal-effects-antidepressants","label":"[11]"},{"url":"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care","label":"[2]"},{"url":"https://www.mentalhealth.com/library/maois#nardil-phenelzine-sulfate-tablets-usp-fda","label":"[4]"},{"url":"https://www.mentalhealth.com/library/maois#emsam-selegiline-transdermal-system-fda","label":"[10]"},{"url":"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care","label":"[2]"},{"url":"https://www.mentalhealth.com/library/maois#mao-inhibitors","label":"[1]"},{"url":"https://www.mentalhealth.com/library/maois#use-monoamine-oxidase-inhibitors-primary-care","label":"[2]"},{"url":"https://www.mentalhealth.com/library/maois#nardil-phenelzine-sulfate-tablets-usp-fda","label":"[4]"},{"url":"https://www.mentalhealth.com/library/maois#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/maois#self-care-depression","label":"[13]"},{"url":"https://www.mentalhealth.com/people/leila-khurshid","label":""},{"url":"https://www.mentalhealth.com/people/leila-khurshid","label":"Leila Khurshid, Pharm.D."},{"url":"https://www.mentalhealth.com/people/leila-khurshid","label":"View profile"},{"url":"https://www.mentalhealth.com/library/maois#self-care-depression","label":"[13]"},{"url":"https://www.mentalhealth.com/library/maois#self-care-depression","label":"[13]"},{"url":"https://www.mentalhealth.com/library/maois#treatment-options-parkinson-s","label":"[14]"},{"url":"https://www.mentalhealth.com/library/maois#medications-parkinson-s","label":"[6]"},{"url":"https://www.mentalhealth.com/library/maois#treatment-options-parkinson-s","label":"[14]"},{"url":"https://www.ncbi.nlm.nih.gov/books/NBK557395/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"National Library of Medicine"},{"url":"https://www.psychiatrist.com/jcp/monoamine-oxidase-inhibitors-primary-care-2/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"psychiatrist.com"},{"url":"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011909s038lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2990566/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"PubMed Central"},{"url":"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/medication/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"apdaparkinson.org"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021479s003s004lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"},{"url":"https://www.ncbi.nlm.nih.gov/books/NBK11035/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"National Library of Medicine"},{"url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2016.00340/full?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"Frontiers"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021336s005s010,021708s000lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"},{"url":"https://www.mind.org.uk/information-support/drugs-and-treatments/antidepressants/withdrawal-effects-of-antidepressants/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"Mind"},{"url":"https://www.nhs.uk/mental-health/conditions/depression-in-adults/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"NHS"},{"url":"https://www.mind.org.uk/information-support/types-of-mental-health-problems/depression/self-care/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"Mind"},{"url":"https://www.apdaparkinson.org/living-with-parkinsons-disease/treatment-medication/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-maois&utm_source=mentalhealth.com","label":"apdaparkinson.org"},{"url":"https://www.mentalhealth.com/clinical-affairs","label":"The Clinical Affairs Team"},{"url":"https://www.mentalhealth.com/publishing/editorial-policy","label":"Editorial Policy"},{"url":"https://www.mentalhealth.com/people/naomi-carr","label":""},{"url":"https://www.mentalhealth.com/people/naomi-carr","label":"Naomi Carr"},{"url":"https://www.mentalhealth.com/people/morgan-blair","label":""},{"url":"https://www.mentalhealth.com/people/morgan-blair","label":"Morgan Blair, M.A."},{"url":"https://www.mentalhealth.com/community/medications","label":""},{"url":"https://www.mentalhealth.com/community/medications","label":"Medications"},{"url":"https://www.mentalhealth.com/library/maois#what-are-maois","label":"What are MAOIs?"},{"url":"https://www.mentalhealth.com/library/maois#what-are-maois-used-to-treat","label":"What are MAOIs used to treat?"},{"url":"https://www.mentalhealth.com/library/maois#how-do-maois-work","label":"How do MAOIs work?"},{"url":"https://www.mentalhealth.com/library/maois#types-of-maois","label":"Types of MAOIs"},{"url":"https://www.mentalhealth.com/library/maois#side-effects-of-maois","label":"Side effects of MAOIs"},{"url":"https://www.mentalhealth.com/library/maois#possible-interactions-with-maois","label":"Possible interactions with MAOIs"},{"url":"https://www.mentalhealth.com/library/maois#alternatives-to-maois","label":"Alternatives to MAOIs"}],"seo":{"title":"MAOIs: Uses, Side Effects and Interactions","description":"Monoamine oxidase inhibitors, commonly referred to as MAOIs, are a type of antidepressant medication used to treat a range of mental health conditions.","canonical":"https://www.mentalhealth.com/library/maois","robots":"index,follow","socialImage":{"url":"https://www.mentalhealth.com/assets/optimized/ec9b0cb47c0207d45e88634d.png","width":1200,"height":630,"alt":"MentalHealth.com — Library","type":"image/png","sitemapGroup":"library"}},"breadcrumbs":[{"name":"Home","url":"https://www.mentalhealth.com/"},{"name":"Library","url":"https://www.mentalhealth.com/library"},{"name":"Medications","url":"https://www.mentalhealth.com/library/medications"},{"name":"Monoamine Oxidase Inhibitors (MAOIs)","url":"https://www.mentalhealth.com/library/maois"}],"subjectMatterExpert":{"name":"Leila Khurshid, Pharm.D.","url":"/people/leila-khurshid","profileId":"2317","topic":"medication","focus":"Clinical pharmacy and medication","selectionBasis":"Documented expertise in the existing published profile","reviewAttribution":false},"keyTakeaways":["MAOIs reduce the breakdown of certain neurotransmitters and are used for selected depressive and neurological conditions.","They are generally not first-choice antidepressants because of side effects and interaction risks.","Medication combinations and tyramine-containing foods can cause serious reactions, requiring careful prescribing and dietary guidance."],"introduction":{"html":"Monoamine oxidase inhibitors, or MAOIs, are a type of antidepressant medication used to treat mental health and neurological conditions. MAOIs are no longer a first choice in treating depression unless in specific and necessary circumstances due to their potential risks. Alternative medications and treatments are available if required.","text":"Monoamine oxidase inhibitors, or MAOIs, are a type of antidepressant medication used to treat mental health and neurological conditions. MAOIs are no longer a first choice in treating depression unless in specific and necessary circumstances due to their potential risks. Alternative medications and treatments are available if required.","sourceField":"hero"},"navigation":[{"label":"What are MAOIs?","href":"#what-are-maois","heading":"What are MAOIs?"},{"label":"What are MAOIs used to treat?","href":"#what-are-maois-used-to-treat","heading":"What are MAOIs used to treat?"},{"label":"How do MAOIs work?","href":"#how-do-maois-work","heading":"How do MAOIs work?"},{"label":"Types of MAOIs","href":"#types-of-maois","heading":"Types of MAOIs"},{"label":"Side effects of MAOIs","href":"#side-effects-of-maois","heading":"Side effects of MAOIs"},{"label":"Possible interactions with MAOIs","href":"#possible-interactions-with-maois","heading":"Possible interactions with MAOIs"},{"label":"Alternatives to MAOIs","href":"#alternatives-to-maois","heading":"Alternatives to MAOIs"}],"relatedCommunity":{"community":"/community/medications","basis":"topic match"},"referencePresentation":"Numbered author–date references with italic work titles, publication details, linked source names, and documented access dates. Missing publication dates use n.d.","collections":[]}
